Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.

ABSTRACT: Immunotherapy represents one of the most promising therapeutic approaches in lung cancer, however 50% of lung cancer patients will not respond to this treatment, while others will have transitory or durable responses. Because side effects may be life threatening and treatment costs remain very high, the identification of predictive markers is mandatory and actually extensively studied. Factors that determine response to immune checkpoint inhibitors (ICI) are numerous including tumor microenvironment, immune tumor infiltrates, expression of immune checkpoint proteins (PD-1/PD-L1), gene expression signatures and molecular tumor profiles. Based on high impact factor publications and recent literature this review focuses on the potential predictive value of tumor molecular alterations and tumo

SUBMITTER: Blons H 

PROVIDER: S-EPMC6353739 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature